This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Innovations Support QIAGEN Shares Despite Macroeconomic Concerns
by Zacks Equity Research
To support internal growth, QGEN heavily invests in R&D for the menu expansion of its key platforms.
Reasons to Retain QIAGEN Stock in Your Portfolio for Now
by Zacks Equity Research
Investors feel optimistic about QGEN's growth prospects in the NGS platforms. Yet, an unfavorable currency impact on the company's operations is concerning.
QGEN Collaborates With McGill University Centre: Stock to Gain?
by Zacks Equity Research
QIAGEN joins forces with McGill University Centre for Microbiome Research to generate evidence-based knowledge for medicine and public health.
Don't Overlook Qiagen (QGEN) International Revenue Trends While Assessing the Stock
by Zacks Equity Research
Evaluate Qiagen's (QGEN) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
Why Qiagen (QGEN) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Hologic Post Q4 Earnings Miss: Time to Buy, Hold or Sell the Stock?
by Moumi Mondal
Despite the recent earnings miss, Hologic's portfolio strength and capital allocation strategy can be appealing to investors.
QIAGEN Stock Flat Post Q3 Earnings & Revenue Beat, 2024 EPS View Up
by Zacks Equity Research
QGEN delivers another solid performance in the third quarter of 2024, with both the top and bottom lines surpassing estimates.
Compared to Estimates, Qiagen (QGEN) Q3 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for Qiagen (QGEN) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Qiagen (QGEN) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Qiagen (QGEN) delivered earnings and revenue surprises of 5.56% and 2.31%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
QGEN Stock Set to Gain From FDA's Clearance of QIAstat-Dx Mini Panel
by Zacks Equity Research
QIAGEN wins FDA clearance for the QIAstat-Dx mini panel to improve precision in outpatient respiratory treatment.
Qiagen (QGEN) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates
by Zacks Equity Research
Beyond analysts' top -and-bottom-line estimates for Qiagen (QGEN), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2024.
EyePoint Pharmaceuticals (EYPT) Soars 27.6%: Is Further Upside Left in the Stock?
by Zacks Equity Research
EyePoint Pharmaceuticals (EYPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Illumina's Q3 Earnings Coming Up: Time to Buy, Sell or Hold the Stock?
by Moumi Mondal
In the third quarter of 2024, ILMN is likely to have benefited from the significant step-up in consumables with growing customer activity on NovaSeq X.
Should You Buy, Sell or Hold HOLX Stock Ahead of Q4 Earnings?
by Moumi Mondal
Hologic's upcoming fourth-quarter fiscal 2024 financial report is expected to reflect strength in core franchises.
ILMN Stock Trading Near 52-Week High: Should You Buy, Sell or Hold?
by Moumi Mondal
Reaching a new one-year high, Illumina remains in investors' sight owing to its strong strategic execution and positive growth outlook.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
QIAGEN's TB Testing Business Gets New Exposure at Global Summit
by Zacks Equity Research
QGEN distributes over 125 million QuantiFERON-TB tests across more than 130 countries worldwide, significantly contributing to national TB control strategies.
OPK Gets Additional BARDA Funding to Develop Multispecific Antibodies
by Zacks Equity Research
OPKO Health's receipt of the additional funding from BARDA is expected to explore the MSTAR platform to prepare for outbreaks and respond rapidly to emerging viral threats.
Should You Bet on HOLX Stock This Breast Cancer Awareness Month?
by Moumi Mondal
Hologic has kicked off the annual breast cancer awareness month with a new campaign. But how well is the stock doing now?
Reasons to Retain QIAGEN Stock in Your Portfolio for Now
by Zacks Equity Research
Investors feel optimistic about QGEN's strong growth prospects in the NGS platforms. Yet, an unfavorable currency impact on the company's operations is cornering.
QIAGEN Launches QIAcuityDx Digital PCR System: Stock to Gain?
by Zacks Equity Research
QGEN expands its digital PCR portfolio with the newly launched QIAcuityDx Digital PCR System. The system will be used for clinical testing in oncology across North America and Europe.
QGEN Stock to Gain From New IVDR Win for QIAstat-Dx Systems and Panels
by Zacks Equity Research
QIAGEN receives European IVDR certification for QIAstat-Dx syndromic testing instruments and assays.
QIAGEN Stock Likely to Gain From PreAnalytiX's Newly Launched PAXgene
by Zacks Equity Research
PreAnalytiX, a joint venture of QGEN and BD, introduces the PAXgene Urine Liquid Biopsy Set. QGEN will commercialize the latest set.
QGEN Stock Might Rise on Partnership With Bode for GEDmatch PRO
by Zacks Equity Research
QIAGEN announces exclusive global commercial partnership with Bode Technology. Per the agreement, Bode will manage all commercial transactions for QIAGEN's GEDmatch PRO globally.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.